Clearsight Advises CREO in its Recapitalization by Grant Avenue Capital

Clearsight Advisors, Inc. (“Clearsight”) is proud to announce a successful transaction in its industry-leading Healthcare & Life Sciences practice. Clearsight served as the exclusive financial advisor to CREO, Inc. (“CREO” or the “Company”) in its recapitalization by Grant Avenue Capital, LLC (“Grant Avenue”).

CREO is a leading management consultancy serving growing life sciences, healthcare, and private equity portfolio companies across the US and international markets. CREO provides holistic solutions across strategy development, M&A services, digital transformation, cybersecurity, IT quality, and regulatory compliance to help clients solve growth challenges and advance clinical innovations. CREO has been named to the Inc. 5000 list of America’s fastest-growing private companies for the past four years and included several times on the Triangle Business Journal’s Fast 50 list of the fastest-growing companies in the Triangle region. Grant Avenue is a healthcare-focused private equity firm partnering with companies that enhance patient health and positively impact their communities. This investment will accelerate CREO’s growth and further expand its advisory services to help advance innovation in human health.

Susan Acker-Walsh, Co-Founder and CEO at CREO, remarked on the transaction, “Over the past few years, we’ve developed a deep relationship with the Clearsight team built upon mutual respect and a thorough understanding of CREO’s business model and goals. When it came time to select an advisor for the next stage of CREO’s growth, we trusted Clearsight to maximize the value of our business. In turn, we received the help of a team of bankers dedicated to achieving an outcome that exceeded our expectations.”

Mike Townley, Co-Founder and President at CREO, added, “Working with Clearsight on this transaction was a game-changer for our business. Their market experience and notable relationships in the life sciences sector elevated the deal process and allowed us to find a great fit with Grant Avenue.”

Clearsight Managing Director John Rakowski noted, “It was a pleasure to collaborate with Susan, Mike, and the greater CREO team on this deal. Their leadership and strategic vision have created a key player in the life sciences advisory space, providing innovative management and growth solutions to a range of clients. We are excited to watch all that the CREO team accomplishes in their new partnership with Grant Avenue.”

The Clearsight deal team included John Rakowski, Greg Treger, Austin Kuhn, Thomas Foreman, and Ben Elasy.